loading page

MicroRNA-143-3p alleviates murine collagen-induced arthritis by polarizing naive CD4+T cells into Treg cells
  • +6
  • Mei Yu Shen,
  • Bao Ping Jiang,
  • Ming Fei Zhang,
  • Xiang Wang,
  • Hong Zhu,
  • Zhen Ning Gu,
  • Xue Ping Zhou,
  • Yan Lu,
  • zhou ling
Mei Yu Shen
Nanjing University of Chinese Medicine
Author Profile
Bao Ping Jiang
Nanjing University of Chinese Medicine
Author Profile
Ming Fei Zhang
Nanjing University of Chinese Medicine
Author Profile
Xiang Wang
Nanjing University of Chinese Medicine
Author Profile
Hong Zhu
Affiliated Hospital of Nanjing University of Chinese Medicine
Author Profile
Zhen Ning Gu
Affiliated Hospital of Nanjing University of Chinese Medicine
Author Profile
Xue Ping Zhou
Nanjing University of Chinese Medicine
Author Profile
Yan Lu
Affiliated Hospital of Nanjing University of Chinese Medicine
Author Profile
zhou ling
Nanjing University of Chinese Medicine
Author Profile

Abstract

Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease with the decreasing proportion of regulatory T (Treg) cells. Previous studies have shown that microRNAs (miRNAs, miR) act as key regulators of Treg cells. In this study, we assessed the involvement of miR-143-3p on Treg cells differentiation and function in the RA progress. We reported that the expression of miR-143-3p has been negatively associated with RA disease activity, and actively correlated with anti-inflammatory cytokine IL-10, which was secreted by Treg cells. In vitro, miR-143-3p expression in the CD4+T cells contributed to the upregulation of forkhead box protein 3 (Foxp3), which was the characteristic transcription factor of Treg cells. Notably, miR-143-3p mimics treatment markedly upregulated the frequency of Treg cells in vivo, effectively prevented CIA development and significantly inhibited inflammation in mice. Altogether, we proposed that MiR-143-3p can alleviate CIA by polarizing naive CD4+T cells into Treg cells, which warrants miR-143-3p as a target for the new therapeutic strategy of Treg-deficiency autoimmune diseases such as RA.

Peer review status:IN REVISION

10 May 2021Submitted to Clinical & Experimental Immunology
10 May 2021Assigned to Editor
10 May 2021Submission Checks Completed
11 May 2021Reviewer(s) Assigned
04 Jun 2021Review(s) Completed, Editorial Evaluation Pending
07 Jun 2021Editorial Decision: Revise Major